News

http://lipa.com.au/uploads/images/Gallery/content_images/web-RotatingGallery2.jpg

News

Oct 31, 2014

Qualitas Health Partners with Lipa Pharmaceuticals To Distribute Almega PL in Australia and New Zealand


Category: General

IMPERIAL, Texas – Oct. 29, 2014 – Qualitas Health has finalized an exclusive distribution agreement with Lipa Pharmaceuticals for its Almega PL omega-3 ingredient for sale to the dietary supplement industry in Australia & New Zealand.  

Lipa Pharmaceuticals is Australia’s leading, full service, integrated, contract manufacturer of dietary supplements and OTC pharmaceutical products with core manufacturing competencies including tablets, soft gelatin capsules, two piece hard gelatin capsules, powders, liquids and creams. Lipa Pharmaceuticals will be responsible to obtain the appropriate regulatory approvals from the Australian Therapeutic Goods Administration (TGA), provide logistic and sales support as well as offering dose-form solutions.  

Almega PL, manufactured by Qualitas Health, is a vegetarian, EPA-rich, polar lipid-structured omega-3 oil. Sourced from Nannochloropsis oculata, a non-GMO strain of microalgae selected for its high level of EPA omega-3 and unique polar-lipid structure, Almega PL contains omega-3 fatty acids with phospholipids and glycolipids that provide superior absorption and digestibility. Farmed microalgae are a source of omega-3s that do not deplete the fragile marine ecosystem. Almega PL is sustainably produced, using natural sunlight, non-arable land and low-energy processes. 

“We are excited to partner with Lipa Pharmaceuticals,” said Yuri Shoshan, CEO, Qualitas Health. “They have very deep relationships with all of the major brands in Australia. This agreement extends our Almega PL sales efforts to a large, vibrant and growing omega-3 market which is increasingly demanding a vegetarian and sustainable alternative.”

“We see great potential for Almega PL in Australia,” said Dusko Pejnovic, CEO, Lipa Pharmaceuticals. “Almega PL offers the unique combination of an EPA-rich, vegetarian and environmentally sustainable omega-3 source. The improved bioavailability from the polar lipids is an essential benefit, as Australia has a well-established krill oil market and consumers are aware of the importance of bioavailability. We look forward to bringing this exciting new ingredient to the Australian market.”

About Qualitas Health

Qualitas Health develops high-value vegetarian food supplements and pharmaceutical ingredients based on microalgae. With deep experience and expertise in algae cultivation and extraction gained from the biofuels sector, Qualitas has developed a unique and proprietary technology for strain selection, sustainable algae farming, harvesting and oil processing. This allows for the effective production of premium omega-3 algae oil for a wide range of applications. For more information: www.qualitas-health.comwww.almegapl.com.

About Lipa Pharmaceuticals

Lipa Pharmaceuticals is Australia's leading contract manufacturer of complementary healthcare medicines and supplies the Asia Pacific region with a wide range of nutraceuticals, non-sterile prescription and OTC medicines. Operating in Sydney’s southwest, Lipa’s 15,000 square meter facility is world class and TGA licensed. With a reputation in the Australasian market as an industry leader and innovator, Lipa has a proven track record of bringing novel ingredients to market, forged through their close relationship with leading marketers across the Asia Pacific Region. For more information: http://www.lipa.com.au.